Compare GSK plc (GSK) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Ferrari NV — how do they compare? GSK plc trades at $52.53 (market cap $101.34B), while Ferrari NV trades at $380 (market cap $65.93B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | RACE | |
|---|---|---|
Market Cap | $101.34B | $65.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $517.65 |
52-Week Low | $36.20 | $314.63 |
Enterprise Value | $121.95B | $67.14B |
Dividend Yield | 3.49% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Ferrari (RACE) trades at $377.03, up 2.13% on the day, with a bullish technical signal supported by moving averages and oscillators. The company demonstrates strong fundamentals, with consistent revenue growth to $7.15B in 2025, robust net income margins above 22%, and a high ROE of 41.96%. Recent quarterly earnings have consistently beaten expectations, and the company is actively executing a multi-billion euro share buyback program.
The outlook is positive, supported by a strong analyst consensus (72% Buy rating) and a price target implying ~24% upside. Key opportunities include pricing power, high margins, and strategic EV transition. Risks include execution of the new EV strategy, potential brand dilution, and premium valuation multiples (P/E of 36.7) that leave little room for error.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
